Pfizer Inc (PFE)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 61,538,000 | 32,884,000 | 36,195,000 | 37,133,000 | 35,955,000 |
| Total stockholders’ equity | US$ in thousands | 89,014,000 | 95,661,000 | 77,201,000 | 63,238,000 | 63,143,000 |
| Debt-to-equity ratio | 0.69 | 0.34 | 0.47 | 0.59 | 0.57 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $61,538,000K ÷ $89,014,000K
= 0.69
The debt-to-equity ratio of Pfizer Inc. has fluctuated over the past five years. In 2023, the ratio increased to 0.81 from 0.37 in 2022, indicating a higher level of debt relative to equity. This may suggest that Pfizer has taken on more debt in 2023 compared to the previous year.
The ratio has shown a general upward trend from 2020 to 2023, with the ratio peaking at 0.83 in 2019. This suggests that Pfizer's reliance on debt as a source of financing has been increasing during this period.
Overall, the trend in the debt-to-equity ratio indicates that Pfizer has been increasingly leveraging its operations with debt over the past few years, potentially to fund growth initiatives or other strategic endeavors. Investors and analysts may monitor this ratio closely as high levels of debt can indicate increased financial risk for the company.
Peer comparison
Dec 31, 2023